2020
The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy
DUSEK, Jaroslav, Zuzana MOTOVSKA, Ota HLINOMAZ, Roman MIKLÍK, Milan HROMADKA et. al.Základní údaje
Originální název
The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy
Autoři
DUSEK, Jaroslav (203 Česká republika), Zuzana MOTOVSKA (203 Česká republika, garant), Ota HLINOMAZ (203 Česká republika, domácí), Roman MIKLÍK (203 Česká republika, domácí), Milan HROMADKA (203 Česká republika), Ivo VARVAROVSKY (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Frantisek TOUSEK (203 Česká republika), Bohumil MAJTAN (203 Česká republika), Stanislav SIMEK (203 Česká republika), Marian BRANNY (203 Česká republika), Jan MROZEK (203 Česká republika) a Petr WIDIMSKY (203 Česká republika)
Vydání
International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2020, 0167-5273
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.164
Kód RIV
RIV/00216224:14110/20:00116817
Organizační jednotka
Lékařská fakulta
UT WoS
000580586000001
Klíčová slova anglicky
Acute myocardial infarction; Primary percutaneous coronary intervention; Periprocedural myocardial infarction; Prognosis
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 7. 2023 12:59, Mgr. Tereza Miškechová
Anotace
V originále
Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. Methods and results: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and intense antithrombotics, and its impact on early outcomes of patients with acute MI treated with primary angioplasty (pPCI). Data from the PRAGUE-18 (prasugrel versus ticagrelor in pPCI) study were analyzed. The primary net-clinical endpoint (EP) included death, spontaneous MI, stroke, severe bleeding, and revascularization at day 7. The key secondary efficacy EP included cardiovascular death, spontaneous MI, and stroke within 30 days. The incidence of peri-pPCI MI was 2.3% (N = 28) in 1230 study patients. The net-clinical EP occurred in 10.7% of patients with, and in 3.6% of patients without, peri-pPCI MI (HR 2.92; 95% CI 0.91-9.38; P = 0.059). The key efficacy EP was 10.7% and 3.2%, respectively (HR 3.44; 95% CI 1.06-11.13; P = 0.028). Patients with periprocedural MI were at a higher risk of spontaneous MI (HR 6.19; 95% CI 1.41-27.24; P = 0.006) and stent thrombosis (HR 10.77; 95% CI 2.29-50.70; P = 0.003) within 30 days. Age, hyperlipidemia, multi-vessel disease, post-procedural TIMI <3, pPCI on circumflex coronary artery, and periprocedural GP IIb/IIIa inhibitor were independent predictors of peri-pPCI MI. Conclusions: In the era of intense antithrombotic therapy, the occurrence of peri-pPCI MI is despite highly sensitive diagnostic markers a rare complication, and is associated with an increased risk of early reinfarction and stent thrombosis. (C) 2020 Elsevier B.V. All rights reserved.
Návaznosti
LM2018128, projekt VaV |
|